logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Rife Resources Ltd. (Group) (00387.HK) will pay a mid-year dividend of 0.1 Hong Kong dollars per share on September 12th.

date
19/08/2025
The Zhitong Finance APP reported that Li Feng (Group) (00387.HK) announced that the company will distribute an interim dividend of 0.1 Hong Kong dollars per share on September 12, 2025.
Latest
3 m ago
Matsubara Safety: Net profit increased by 30.85% year-on-year in the first half of the year.
3 m ago
In pre-market trading on Tuesday, U.S. stocks, Xiaoying Technology rose by 8.8%. The company's second quarter revenue increased by 65.6% year-on-year, with the total amount of loans facilitated and disbursed reaching a record 38.99 billion yuan, an increase of 71.4% year-on-year; the number of active borrowers increased by 73.7% year-on-year, reaching 2.85 million.
3 m ago
Before the US market on Tuesday, small-cap stock Upstart Technology rose 8.8%. The company's second-quarter revenue increased by 65.6% year-on-year, with a record-breaking total loan amount of 38.99 billion yuan granted and disbursed, a year-on-year increase of 71.4%; the number of active borrowers increased by 73.7% year-on-year to 2.85 million.
4 m ago
Zhongguang Lightning Protection: The company's customized and developed high-performance, ultra-large current flow T1 AC SPD is currently in the sample stage.
4 m ago
Due to lower-than-expected mid-term trial data for Viking Therapeutics' (VKTX.US) experimental oral weight loss drug, the stock plummeted nearly 34% in pre-market trading on Tuesday. Viking stated in a release that their oral GLP-1R/GIPR dual agonist VK2735 can help patients lose up to 12.2% of their weight. However, about 28% of patients dropped out of the trial in just three months, diminishing confidence in the drug's ability to compete with drugs from Eli Lilly (LLY.US) and Novo Nordisk (NVO.US). Mizuho Securities analyst Jared Holz noted, "It's worth noting the high dropout rate of patients within the 13-week period."
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.